Amino Acid Supply-Demand Dynamics Awaiting Recovery
发布时间:2026-11-08 来源:华泰证券
For 3Q26,revenue/attributable net profit were RMB4,120/-14.81mn(+5/-108%YoY,-7/-113%QoQ).For 9M26,revenue/attributable net profit/recurring net profit were RMB12,310/55.91/1.77mn(+2/-94/-99.8%YoY).Star Lake’s 3Q26 attributable net profit missed our estimate of RMB20mn,mainly due to lower prices for its core products.Given rising penetration in the livestock farming sector,a favorable supply landscape,and incremental contributions from new projects,we maintain our BUY rating on the shares.
Feed additive demand under pressure in 9M26
For 9M26,feed additive revenue rose by 3%YoY to RMB8.5bn.Per boyar.cn,average prices for 98.5%lysine/70%lysine/threonine were RMB6.97/4.55/8.07/kg(-18/-14/-20%YoY),having been weighed down by softer demand.For 3Q26,segment revenue rose by 6%YoY to RMB2.9bn,while average market prices for 98.5%lysine/70%lysine/threonine stood at RMB6.43/4.33/7.20/kg(-12/-15/-21%YoY),reflecting lingering demand pressure in 3Q26.
9M26 blended GPM declined by 9.5pp YoY to 9.5%
For 9M26,food additive segment revenue fell by 3%YoY to RMB2.8bn,mainly due to lower YoY monosodium glutamate(MSG)prices;per baiinfo,the average market price of MSG fell by 3%YoY to RMB6,800/tonne on capacity additions and soft demand.For 3Q26,food additive segment revenue edged up by 0.3%YoY to RMB970mn,with the average market price of MSG rising by 1%YoY to RMB6,900/tonne on stronger pricing discipline among producers.For 9M26,revenues from organic fertilizers/pharmaceutical intermediates/biochemical drugs were RMB250/120/110mn(-2/-24/+13%YoY).Weighed down by lower YoY prices for its core products,9M26 blended GPM fell by 9.5pp YoY to 9.5%.
Amino acid and MSG S/D dynamics awaiting recovery
Per Boyar,as of 27 October,prices for 98.5%lysine/70%lysine/threonine/MSG were RMB6.85/4.45/8.30/6.63/kg(+0/-1/+0/+0%versus end-September).Supported by rising penetration in livestock farming,stronger producer price-support discipline,and afavorable supply landscape,we expect product momentum for amino acids and MSG to recover gradually,with potential sequential improvement in 4Q26.Per the 1H26 report,the 600ktpa corn deep-processing and supporting cogeneration project in Kokdala progressed smoothly,completing final acceptance in 1H26 with key production lines ramping up towards full capacity;meanwhile,the 450ktpa amino acid and supporting engineering project in Daqing,Heilongjiang is advancing on schedule,with all individual sub-projects having commenced construction.In addition,restructuring synergies following its 2022 acquisition of Eppin Biotech are materializing.Backed by expanded operating scale and improved earnings,its 2023/2024/2025 dividend payout ratios rose markedly versus 2022 to 93/67/65%.Upcoming incremental contributions from new projects should support avaluation re-rating,in our view.
Earnings forecasts and valuation
As downstream demand for amino acids and MSG awaits recovery,we lower our GPM assumptions for amino acids and MSG,trimming our 2026/2027/2028 attributable net profit forecasts by 82/40/14%to RMB100/490/780mn(previous:RMB550/810/910mn;-90/+387/+59%YoY),corresponding to EPS of RMB0.06/0.29/0.47.Given the gradual recovery pace of the amino acid and MSG cycle,we expect astronger upturn in 2028.To reflect growth potential from its projects under investment,we value the stock at 11x 2028E PE,above its peers'average of 9x.Our target price is RMB5.17(previous:RMB5.28,based on 16x 2026E PE).Maintain BUY.
Risks:slower-than-expected progress in new projects,loss of core technologies.